Pharmacogenetic studies of suicide: Potential relevance of main polymorphic CYPs and ABCB1

Abstract:

The present review focuses on existing information about studies of polymorphic genes mostly involved in the pharmacokinetics of widely clinically prescribed drugs for the treatment of suicide that have been related to suicide and suicidal behaviors. It also presents an overview of studies that found associations of other genes (e.g., BDNF, NTRK2, CREB1, ADRA2A, GRIA3, GRIK2, GDA, IL28RA, FKBP5, PAPLN) with emergence or worsening of suicidal ideation during treatment with antidepressants. The most studied pharmacokinetics-related genetic polymorphisms have been CYP2D6 and recently CYP2C19 and ABCB1. An increased frequency of CYP2D6 ultrarapid metabolizers has been described in forensic suicide samples, eating disordered patients with a lifetime history of suicidal behavior, depressive inpatients with high suicide risk, and attempters from the general population with high scores on the Beck Suicide Intent Scale - Objective circumstances section. Furthermore, the latter suicide phenotype was associated in another population of attempters with a high CYP2D6-CYP2C19 combined metabolic capacity, particularly in those without a family history of suicidal behavior. Recently, the ABCB1 has been found in relation to violent methods of attempted and completed suicide.

Año de publicación:

2016

Keywords:

Fuente:

scopus